pddakttk

Ultrasound Societies Urge FDA to Remove Black Box Warning on Contrast Agents

first_img The Liver Imaging Reporting and Data System (LI-RADS) contrast-enhanced ultrasound (CEUS) working group. Technology | Interventional Radiology | August 16, 2019 Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to… read more The Society of Diagnostic Medical Sonography (SDMS); News | Ultrasound Imaging | March 07, 2019 Ultrasound Societies Urge FDA to Remove Black Box Warning on Contrast Agents Citizen petition argues that current research has demonstrated ultrasound contrast agents safe and effective News | Pediatric Imaging | August 14, 2019 Ultrasound Guidance Improves First-attempt Success in IV Access in Children August 14, 2019 – Children’s veins read more Feature | Contrast Media | July 18, 2019 | By Greg Freiherr How To Manage Risk in the MR Suite Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n read more News | Ultrasound Imaging | July 31, 2019 Studies Confirm Clinical Value of ShearWave Elastography for Liver Fibrosis Evaluation SuperSonic Imagine announced the publication of the results of its prospective multicentric clinical study conducted in… read more News | Ultrasound Women’s Health | July 11, 2019 FDA Clears Koios DS Breast 2.0 AI-based Software Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA). The World Federation of Ultrasound in Medicine and Biology (WFUMB); The American Society of Echocardiography (ASE); and Technology | Contrast Media | July 15, 2019 FDA Approves Bayer’s Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance… read more News | Cardiovascular Ultrasound | August 07, 2019 Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for… read more Technology | Contrast Media | August 05, 2019 Bracco Receives FDA Approval for Varibar Thin Liquid for Oral Suspension Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium… read more News | Cardiovascular Ultrasound | August 05, 2019 Digital Health Devices Used at Point of Care May Improve Diagnostic Certainty A West Virginia-based rural medical outreach event showcased the use of point-of-care technology in an ambulatory… read more Numerous individual physicians also submitted letters supporting the ICUS petition.“We are disappointed that ‘black box warnings’ are still mandated for ultrasound contrast agents, despite extensive scientific research and practice demonstrating their safety,” according to Brian Coley, M.D., AIUM president, professor of medicine and radiologist-in-chief at Cincinnati Children’s Hospital.According to the ICUS Petition, UCAs are injected into a patient’s arm vein during a diagnostic ultrasound scan to help diagnose heart disease, pinpoint and characterize cancers, monitor chronic gastro-intestinal diseases, detect vascular disease, evaluate other serious medical conditions and monitor therapy. By improving the reliability of real-time ultrasound scans, UCAs often reduce the need for unnecessary downstream tests and related costs, speed up the time to diagnosis and access to appropriate therapy, reduce the length of hospital stays, and improve patient care, outcomes and experiences.UCAs do not contain radioactive material or dye, present no known risk of kidney or liver damage, and do not require sedation. The agents are metabolized and expelled from the body, primarily through the lungs, within minutes.“Our collective experience shows that UCAs are exceedingly safe and beneficial, and they can change patient outcomes and improve patient experiences,” according to a statement submitted by the SRU on behalf of American radiologists with expertise in ultrasound.The SRU statement added that CEUS is often “equivalent to or superior to CT [computed tomography] and MRI [magnetic resonance imaging], yet it is less expensive, more patient-friendly, more widely available and completely radiation-free.”According to the ICUS Petition, a “black box” warning is appropriate only as an indicator of the very highest level risk associated with FDA-approved products, and studies now show “no increased safety signal even among the sickest patients.” The petition describes safety studies undertaken after 2007 at the request of the FDA, as well as other independent studies recently published in peer-reviewed journals.”The data now clearly and consistently show that UCAs are extremely safe — even in the sickest patients,” according to Michael Main, M.D., a cardiologist at Saint Luke’s Mid America Heart Institute in Kansas City. Main is a vice president of ICUS and the principal author of recent studies examining the safety of UCAs.Richard Barr, M.D., a radiologist in Youngstown, Ohio, wrote that his physician group has used CEUS in more than 3,000 patients over more than 10 years, without a single significant adverse event. Barr is also the editor-in-chief of the Journal of Ultrasound in Medicine and stated that he supports the ICUS petition.In addition, Barr said that CEUS prevented a large number of biopsies and surgeries, and allowed his group to confirm benign lesions with confidence and detect other lesions at an earlier stage so that appropriate therapy could be provided more quickly. He noted that CEUS is also an important tool for patients who are unable to tolerate contrast CT or MR, such as patients with kidney insufficiency.CEUS also offers a “huge advantage” for pediatric patients, according to Kassa Darge, M.D., Ph.D., radiologist-in-chief at Children’s Hospital of Philadelphia. He said CEUS can reduce or eliminate radiation exposure, avoid sedation or anesthesia, avoid gadolinium contrast deposits — and ultimately is “much more sensitive or depicts the pathology clearer” in many pediatric ultrasound scans.Darge said that the “high safety profile” of CEUS in children has now been documented in scientific publications encompassing thousands of children, and there are “no real scientific reasons for having this label.”Yet because of the black box, some physicians are unduly reluctant to refer patients for CEUS and some patients are apprehensive about receiving UCAs, according to Barr and other experts who weighed in on the petition.“The unnecessary presence of a black box results in unfounded fears of utilization of these extremely beneficial agents, and patients are thus exposed to potentially more harmful investigative procedures, or worse, have no information due to uninterpretable, or misinterpreted ultrasound studies, resulting in missed or wrong diagnoses,” according to Sharon Mulvagh, M.D., professor of medicine emeritus, Mayo Clinic in Rochester, Minn., and professor of medicine, Dalhousie University in Halifax, Canada.Watch the VIDEO: Use of Ultrasound to Assess Heart Disease Risk, an interview with Mulvagh at ASE 2017.“The Black Box serves no useful purpose,” according to a letter submitted by Yuko Kono, M.D., clinical professor of medicine and radiology at the University of California, San Diego; Stephanie Wilson, M.D., clinical professor of radiology and medicine at the University of Calgary; and Andrej Lyshchik, M.D., Ph.D., associate professor of radiology at Thomas Jefferson University Hospital in Philadelphia. Kono, Wilson and Lyshchik are members and chair of the CEUS LI-RADS Working Group.According to Wilson, the United States is behind the rest of the world when it comes to using CEUS, which she described as a very patient-friendly, extremely reliable and easy-to-use imaging tool.“We believe the boxed warning is not warranted and only discourages the use of CEUS,” according to Beth McCarville, M.D., and Peter Strouse, M.D., writing on behalf of SPR, the pediatric radiology organization. According to them, a growing body of literature now validates the excellent safety profile of UCAs, which offer a “safe, sedation-free and radiation-free, low-risk method of assessing a variety of conditions in children and should be embraced and supported by pediatric care providers.”The ICUS petition notes that the FDA has steadily responded to the mounting evidence of UCA safety and efficacy by downgrading package insert contraindications three times since 2007, and removing a 30-minute monitoring requirement for patients with pulmonary hypertension or unstable cardiopulmonary conditions. More recently, the FDA approved new indications for use in adults and children.Three UCAs are currently approved for use in the United States — Definity (Lantheus Medical Imaging), Lumason (Bracco) and Optison (GE Healthcare).For more information: www.icus-society.org FacebookTwitterLinkedInPrint分享 Related Content read more The ScanTrainer transvaginal simulator is one example of Intelligent Ultrasound’s simulation technologies. Related Echo Contrast Content:The Status and Future of Contrast EchocardiologyRecent Developments and Issues in Contrast MediaWatch the VIDEO: Therapeutic Applications for Contrast UltrasoundMicro-Bubble Echo Contrast Procedures Rebounded in 2008Busting Blood Clots in the AmbulanceUltrasound-Activated Bubbles Aid Clot-BustersStudy Demonstrates Strain Imaging Utility With Contrast-Echo StudiesStudy Says Usage of Ultrasound Contrast Agents in Echocardiography DeclinedUltrasound-activated Microbubbles Restore Blood Flow During Heart AttackTrends and Advances in Echocardiography at ASE 2015 March 7, 2019 — National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black box” from ultrasound contrast agent (UCA) labels.“UCAs are among the safest diagnostic imaging products available,” according to a citizen petition filed by the International Contrast Ultrasound Society (ICUS).UCAs are used worldwide to enhance diagnostic ultrasound scans, according to the petition, which cited an extensive body of favorable safety data that was not available in 2007 when the boxed warnings were first mandated by the FDA.“It is clear to all who work in the field on a daily basis that the black box harms patient care by misrepresenting risk and inappropriately deterring the use of UCAs when they are medically indicated,” said Steven Feinstein, M.D., co-president of ICUS and professor of medicine at Rush University Medical Center in Chicago. “There is now a strong consensus from across the adult and pediatric medical ultrasound community that ultrasound contrast agents are extremely safe and do not warrant boxed warnings,” he added.Medical societies supporting the ICUS Petition include: The American Institute of Ultrasound in Medicine (AIUM); Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco News | Ultrasound Imaging | July 26, 2019 Intelligent Ultrasound Group Collaborating With the National Imaging Academy Wales Artificial intelligence (AI)-based ultrasound software and simulation company Intelligent Ultrasound Group plc (AIM:… read more The Society of Radiologists in Ultrasound (SRU); The Society for Pediatric Radiology (SPR);last_img

Leave a Reply

Your email address will not be published. Required fields are marked *